What Is Ipamorelin?

What Is Ipamorelin? (Selective GHS-R1a Signaling)

Endocrinologists studying synthetic growth hormone secretagogues—molecules that stimulate the pituitary gland via the ghrelin receptor (GHS-R1a)—observed that earlier secretagogues such as GHRP-6, GHRP-2, and Hexarelin produced strong growth hormone spikes, but also cross-stimulated the hypothalamic-pituitary-adrenal axis, elevating cortisol, prolactin, and appetite.

Ipamorelin is a synthetic pentapeptide developed as a more selective growth hormone secretagogue. In published endocrine research (PubMed), Ipamorelin stimulated pituitary somatotrophs to release growth hormone in a pulsatile pattern while showing much greater selectivity than earlier GHRPs with respect to cortisol and prolactin release.

How Ipamorelin Compares With Other Growth Hormone Secretagogues

Published Preclinical & Human Clinical Literature

• Pulsatile Somatotroph Signaling & Endocrine Selectivity: Unlike exogenous recombinant human growth hormone (which creates a prolonged supraphysiological elevation that suppresses endogenous pituitary feedback), GHS-R1a secretagogues preserve the body's pulsatile secretory pattern and negative-feedback loops via hepatic IGF-1 (PubMed).
• Growth Hormone Physiology, Body Composition & Tissue Turnover: Endocrine reviews examining growth hormone and IGF-1 signaling describe how pulsatile somatotropic activity influences nitrogen retention, lipolysis, collagen turnover, and recovery physiology (NIH PMC2699646; Examine.com Growth Hormone Review).
• Absence of Established Long-Term Human Safety: Although Ipamorelin has been studied in early clinical and endocrine settings, it has never received FDA approval for any medical indication, and its long-term human safety profile remains unestablished.
• Multi-Receptor Co-Administration Research: In laboratory studies examining dual-pathway pituitary signaling (How Multi-Peptide Research Works), researchers study GHS-R1a agonists like Ipamorelin alongside GHRH analogs like CJC-1295 (including pre-formulated CJC-1295/Ipamorelin research blends) because GHS-R1a activation suppresses hypothalamic somatostatin tone while GHRHR activation drives somatotroph cAMP transcription.

Safety Profile, FDA Compounding Status & WADA Rules

Evaluating Ipamorelin's safety profile requires considering both the known physiological effects of raising growth hormone and IGF-1 and the unknowns of an unapproved compound:

• Reported Short-Term Observations: In published research and clinical observations, reported side effects include headache, transient flushing or warmth, lightheadedness, mild water retention, carpal-tunnel-like tingling or numbness in the hands and extremities, and local injection-site redness or irritation.
• Cancer & Tumor Growth Uncertainty: Because growth hormone and IGF-1 act as mitogenic signals that promote cell division and inhibit apoptosis, active cancer or a history of malignancy is a major caution due to uncertainty around potential tumor growth promotion.
• Diabetes, Blood Glucose & Diabetic Retinopathy: Growth hormone antagonizes insulin action and can impair glucose tolerance or elevate blood sugar; individuals with diabetes, insulin resistance, or proliferative diabetic retinopathy face heightened metabolic and microvascular risk.
• Pregnancy, Breastfeeding & Minors: Ipamorelin has no established safety data in pregnant or breastfeeding women or in children and adolescents (minors).

On the U.S. FDA's Bulk Drug Substances lists current as of April 22, 2026, Ipamorelin acetate is listed in Category 2 under Section 503B (bulk drug substances that raise significant safety risks in compounding, including potential immunogenicity and endocrine/metabolic effects when administered without an approved NDA), and its Section 503A nomination appears in the withdrawn nominations table. The FDA also maintains consumer enforcement advisories regarding unapproved injectable products in its Health Fraud Product Database.

Consequently, Ipamorelin is not an FDA-approved medication and cannot be lawfully compounded as a routine human prescription drug in the United States. In competitive sports, Ipamorelin is prohibited at all times (in- and out-of-competition) under Class S2.2.4 (Growth Hormone Releasing Factors) of the World Anti-Doping Agency (WADA) Prohibited List.

Scientific References and Further Reading

1. Ipamorelin, the first selective growth hormone secretagogue — PubMed
2. Effect of Growth Hormone Secretagogues on Sleep and Aging - PubMed
3. Growth Hormone and Physical Performance - National Institutes of Health
4. Growth Hormone Research Summary — Examine.com
5. Health Fraud Product Database — U.S. Food and Drug Administration
6. The Prohibited List — World Anti-Doping Agency (WADA)